Vyvanse vs Adderall XR in Special Populations: A Head-to-Head Comparison

How Each Drug Actually Works

Both medications deliver amphetamine, but the path from pill to brain differs in ways that matter clinically.

Adderall XR uses a dual-bead system: 50% of the beads release immediately and 50% release approximately 4 hours later, producing two distinct plasma peaks. Vyvanse is an inactive prodrug. After oral ingestion, intestinal and red-blood-cell enzymes cleave the lysine carrier from lisdexamfetamine, releasing d-amphetamine. This enzymatic step cannot be bypassed by crushing, snorting, or dissolving the capsule, which is the pharmacokinetic basis for its lower abuse potential. The FDA's full prescribing information for Vyvanse documents this mechanism explicitly.

Peak Plasma Concentration and Onset

Adderall XR reaches first peak plasma concentration (Cmax) at roughly 3 hours post-dose. Vyvanse produces a single, smoother d-amphetamine peak at approximately 4.4 hours. The smoother curve means Vyvanse carries a lower likelihood of the sharp mid-afternoon stimulant "crash" that some patients report with Adderall XR.

Duration of Action

In laboratory classroom studies, Vyvanse has demonstrated statistically significant effects on ADHD symptoms through 13-14 hours post-dose. Adderall XR's documented efficacy window is closer to 8-12 hours. For patients who need evening coverage for homework or shift work, this difference is clinically relevant.

Efficacy in Children (Ages 6-12)

Head-to-head pediatric data are limited, but the Wigal et al. 2017 crossover study (N=317, ages 6-12) is the most rigorous direct comparison available. Published in the Journal of Attention Disorders, the trial found that both Vyvanse (30-70 mg) and Adderall XR (10-30 mg) produced statistically significant, comparable reductions in ADHD Rating Scale (ADHD-RS-IV) total scores at week 4. Vyvanse produced a mean ADHD-RS-IV change of -23.8 points versus -22.3 points for Adderall XR. The difference was not statistically significant (Wigal et al., J Atten Disord, 2017).

The MTA Benchmark

The Multimodal Treatment of ADHD (MTA) study, published in Archives of General Psychiatry (1999, N=579, ages 7-9.9), remains the landmark pediatric ADHD pharmacotherapy trial. It found that systematic medication management with stimulants produced significantly greater symptom reduction than behavioral therapy alone or community care. The MTA did not compare Vyvanse (not yet approved) but established the evidence base on which both agents now rest (MTA Cooperative Group, Arch Gen Psychiatry, 1999).

Practical Dosing in Children

Adderall XR starts at 5-10 mg once daily in children, titrated in 5-10 mg increments weekly. Vyvanse starts at 20-30 mg once daily, titrated in 10-20 mg increments weekly to a maximum of 70 mg. The capsule-sprinkle feature available in both formulations makes either drug suitable for young children who cannot swallow pills whole.

Efficacy in Adolescents (Ages 13-17)

Adolescent data for Vyvanse come primarily from the key SPD489-325 trial, a randomized, double-blind, placebo-controlled study (N=314, ages 13-17) in which Vyvanse 30-70 mg significantly reduced ADHD-RS-IV scores versus placebo at week 4 (mean difference: -10.41 points, P<0.001). Full trial data are available via the FDA drug approval package.

Adderall XR's adolescent efficacy is established through the key Biederman et al. (J Am Acad Child Adolesc Psychiatry, 2002, N=287) trial, which showed a statistically significant ADHD-RS reduction of 18.6 points versus 10.2 points for placebo at 3 weeks.

No published randomized head-to-head adolescent trial exists. Clinicians should select based on comorbidity profile, abuse risk, and duration needs rather than assuming superiority of one over the other.

Efficacy in Adults (Ages 18-55)

ADHD Symptom Control

Adult ADHD trials for both agents are strong. Adderall XR's key adult trial (Weisler et al., J Clin Psychiatry, 2006, N=255) demonstrated a 20.7-point mean reduction in Conners' Adult ADHD Rating Scale (CAARS) versus 12.0 points for placebo at 4 weeks. Vyvanse's key adult trial (Adler et al., J Clin Psychiatry, 2008, N=414) showed similar CAARS improvements, with 56.4% of Vyvanse-treated patients classified as treatment responders versus 27.8% of placebo patients (Adler et al., J Clin Psychiatry, 2008, PubMed).

Binge Eating Disorder in Adults

Vyvanse holds a unique FDA approval for moderate-to-severe binge eating disorder (BED) in adults, making it the only amphetamine-class agent indicated for this condition. The key BED trials (McElroy et al., JAMA Psychiatry, 2015, N=390 pooled) showed Vyvanse 50 mg and 70 mg reduced binge eating days per week by 3.87 and 4.00 days respectively, versus 1.91 days for placebo (McElroy et al., JAMA Psychiatry, 2015). Adderall XR has no approved indication and no controlled trial data for BED.

Executive Function and Cognition

Both agents improve working memory, inhibitory control, and processing speed in adults with ADHD. A 2022 systematic review in Neuroscience and Biobehavioral Reviews (Cortese et al., N=61 trials) found effect sizes for amphetamines on cognitive outcomes (d = 0.48-0.62) that were modestly superior to methylphenidate agents. Neither Vyvanse nor Adderall XR showed consistent superiority over the other within amphetamine-class comparisons. The review authors stated: "Amphetamines showed the highest probability of being the best treatment for improving attention in adults."

Efficacy in Older Adults (Ages 55 and Above)

Stimulant use in patients over 55 is off-label but practiced. Published data are sparse. A retrospective cohort analysis by Moran et al. (Am J Geriatr Psychiatry, 2019, N=145, mean age 63) found that low-dose stimulants, including both amphetamine salts and lisdexamfetamine, produced clinically meaningful ADHD symptom improvement in 68% of older adults, with a cardiovascular adverse event rate of 7.6%. Blood pressure elevations were the most common adverse event.

Cardiovascular Risk in Older Adults

The FDA label for both drugs carries a cardiovascular warning. Mean increases in heart rate of 3-6 beats per minute and systolic blood pressure of 1-4 mmHg are documented across clinical trials. In a patient with pre-existing hypertension or coronary artery disease, these modest increases may be unacceptable. Adderall XR's dual-peak concentration curve may produce more pronounced transient cardiovascular effects compared to Vyvanse's smoother single peak, though no head-to-head cardiovascular trial in older adults has been published.

Cognitive Benefit vs. Cardiac Risk

Clinicians treating older adults should obtain a baseline ECG, track blood pressure at every visit, and start at the lowest available dose (Adderall XR 5 mg or Vyvanse 20 mg). The American Heart Association's 2008 scientific statement recommends cardiovascular evaluation before stimulant initiation in any patient with a cardiac history (Vetter et al., Pediatrics, 2008, AHA-endorsed).

Special Populations: Pregnancy and Lactation

Neither drug is approved for use during pregnancy. Both are Pregnancy Category C (historical classification) with no adequate, well-controlled human studies. Amphetamine exposure in the first trimester has been associated with small increases in gastroschisis risk in some observational studies. The FDA drug label for Adderall XR states: "Infants born to mothers dependent on amphetamines have an increased risk of premature delivery and low birth weight."

Vyvanse's label carries equivalent language. Both drugs are excreted in human breast milk. The American Academy of Pediatrics classifies amphetamines as drugs of abuse that are contraindicated during breastfeeding, though some clinicians weigh risk and benefit individually for patients with severe ADHD who cannot function without pharmacotherapy.

Special Populations: Patients With Substance Use Disorder

This is the clearest population-level differentiator. Vyvanse's prodrug design produces a blunted, delayed euphoric response compared to an equivalent dose of immediate-release d-amphetamine. A pharmacokinetic abuse-liability study (Jasinski and Krishnan, J Psychopharmacol, 2009, N=36) demonstrated that intranasal lisdexamfetamine 100 mg produced lower drug-liking scores and slower onset of effect than intranasal d-amphetamine 40 mg. Oral misuse at supratherapeutic doses still confers abuse potential, but the pharmacokinetic barrier is real (Jasinski and Krishnan, J Psychopharmacol, 2009).

For patients with a personal or family history of stimulant misuse, Vyvanse is the preferred amphetamine-class option. Adderall XR has no pharmacokinetic barrier to crushing or dissolving beads for more rapid delivery, and prescribers in high-diversion environments generally prefer Vyvanse when stimulant therapy is medically necessary.

Side Effect Profiles Compared

Both drugs share the amphetamine class adverse effect profile: decreased appetite, insomnia, dry mouth, increased heart rate, and irritability. Three differences are worth noting.

Appetite Suppression

Appetite suppression appears slightly more pronounced and prolonged with Vyvanse in some patients, attributable to the longer duration of action. In pediatric growth monitoring studies, both agents produced comparable reductions in height velocity of approximately 1 cm per year in the first year of treatment.

Cardiovascular Effects

As noted above, Adderall XR's dual-peak pharmacokinetics may produce sharper transient rises in blood pressure and heart rate. In the Vyvanse key adult trial, mean systolic blood pressure increase was 1.4 mmHg. In a comparable Adderall XR trial, the mean increase was 1.2 mmHg. Neither difference is large enough to guide individual prescribing decisions based on blood pressure alone.

Rebound and Crash

Patients frequently report more pronounced afternoon rebound with Adderall XR than Vyvanse. This is consistent with the pharmacokinetics: the second bead-release peak of Adderall XR drops off faster than the single, sustained d-amphetamine curve from Vyvanse. No randomized trial has directly quantified rebound severity using a validated scale.

Switching From Vyvanse to Adderall XR (or Vice Versa)

Patients switch between these agents for three primary reasons: insurance coverage changes, side effect profile, or inadequate efficacy. No FDA-approved conversion table exists. The most widely cited clinical practice guideline, published by the American Academy of Child and Adolescent Psychiatry (AACAP, 2007, updated 2020), advises that switching between amphetamine-class stimulants should be done with a dose reduction to account for formulation differences.

Dose Conversion Estimates

Published pharmacokinetic modeling suggests that Vyvanse 70 mg produces a d-amphetamine AUC roughly equivalent to Adderall XR 30-40 mg, because Vyvanse's conversion efficiency is approximately 29-32 mg of d-amphetamine per 70 mg of lisdexamfetamine. A conservative clinical conversion used by many prescribers:

• Vyvanse 30 mg is approximately equivalent to Adderall XR 10-15 mg
• Vyvanse 50 mg is approximately equivalent to Adderall XR 20-25 mg
• Vyvanse 70 mg is approximately equivalent to Adderall XR 30 mg

These estimates are not validated in a head-to-head pharmacokinetic trial. Prescribers should start at the lower end of the estimated equivalent dose and titrate up based on response and tolerability over 2-4 weeks.

When to Switch to Vyvanse

Consider switching from Adderall XR to Vyvanse when: afternoon rebound is functionally new, there is concern about diversion or misuse, or the patient needs evening coverage beyond 10 hours. Vyvanse's once-daily pharmacokinetics simplify the medication schedule for many adults managing busy work schedules.

When to Switch to Adderall XR

Consider switching from Vyvanse to Adderall XR when: cost is a barrier (Adderall XR generics can cost 60-80% less than brand Vyvanse), earlier onset of action is clinically important, or the patient's insurer restricts Vyvanse access. Adderall XR generic amphetamine salts ER are widely available at most pharmacies and may cost under $40/month with discount cards at some locations.

Insurance, Cost, and Access

Adderall XR went off-patent in 2009. Generic mixed amphetamine salts ER are available from multiple manufacturers. Brand Adderall XR carries a retail price above $300/month without insurance. Brand Vyvanse was approximately $400/month before generic lisdexamfetamine launched in August 2023 via an authorized generic from Takeda. As of early 2024, generic lisdexamfetamine may cost $130-200/month depending on pharmacy and dose, though this varies by region and supply.

Many payers require step therapy: a patient must fail a generic amphetamine formulation before Vyvanse (branded or generic) is approved. Physicians can submit prior authorization documentation citing abuse risk, BED indication, or failed prior stimulant trials to obtain coverage.